Dendritic-cell-based therapeutic vaccination against cancer

被引：163

作者：

Nestle, FO ^{[1
]}

Farkas, A ^{[1
]}

Conrad, C ^{[1
]}

机构：

[1] Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland

来源：

CURRENT OPINION IN IMMUNOLOGY | 2005年 / 17卷 / 02期

关键词：

D O I：

10.1016/j.coi.2005.02.003

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Early clinical trials, in which over 1000 cancer patients received dendritic cell (DC) vaccines, tested different vaccine preparations, but they did not always induce sufficient acquired immunity or meet the expected level of tumor regressions. Current studies aim to improve the DC vaccine approach and capture the potential of these cells in order to gain access to lymphoid tissues and induce strong cell-mediated immunity. DC clinical trials are moving towards a more professional environment, in accordance with the latest quality standards. This explains the current need for innovative well designed trials with defined endpoints that induce robust anti-tumor immunity.

引用

页码：163 / 169

页数：7

共 67 条

[1] Maturation matters: Importance of maturation for antitumor immunity of dendritic cell vaccines
Adams, S
O'Neill, D
Bhardwaj, N
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (18) : 3834 - 3835
[2] Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery
Asavaroengchai, W
Kotera, Y
Mulé, JJ
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (02) : 931 - 936
[3] Banchereau J, 2001, CANCER RES, V61, P6451
[4] Dendritic cells and the control of immunity
Banchereau, J
Steinman, RM
[J]. NATURE, 1998, 392 (6673) : 245 - 252
[5] Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients
Bedrosian, I
Mick, R
Xu, SW
Nisenbaum, H
Faries, M
Zhang, P
Cohen, PA
Koski, G
Czerniecki, BJ
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (20) : 3826 - 3835
[6] In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination
Bonifaz, LC
Bonnyay, DP
Charalambous, A
Darguste, DI
Fujii, SI
Soares, H
Brimnes, MK
Moltedo, B
Moran, TM
Steinman, RM
[J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 199 (06) : 815 - 824
[7] Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects
Borg, C
Terme, M
Taïeb, J
Ménard, C
Flament, C
Robert, C
Maruyama, K
Wakasugi, H
Angevin, E
Thielemans, K
Le Cesne, A
Chung-Scott, V
Lazar, V
Tchou, I
Crépineau, F
Lemoine, F
Bernard, J
Fletcher, JA
Turhan, A
Blay, JY
Spatz, A
Emile, JF
Heinrich, MC
Mécheri, S
Tursz, T
Zitvogel, L
[J]. JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (03) : 379 - 388
[8] Dendritic cell culture: A simple closed culture system using ficoll, monocytes, and a table-top centrifuge
Celluzzi, CM
Welbon, C
[J]. JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2003, 12 (05): : 575 - 585
[9] Dendritic cells: a journey from laboratory to clinic
Cerundolo, V
Hermans, IF
Salio, M
[J]. NATURE IMMUNOLOGY, 2004, 5 (01) : 7 - 10
[10] Dendritic cells and immunotherapy for cancer
Chang, DH
Dhodapkar, MV
[J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2003, 77 (05) : 439 - 443

← 1 2 3 4 5 6 7 →